The Natoli Institute for Industrial Pharmacy Research and Development Now Open
Natoli Engineering Company announces the opening of the Natoli Institute for Industrial Pharmacy Research and Development. Opened in partnership with the Arnold and Marie Schwartz College of Pharmacy and Health Sciences on the Brooklyn campus of Long Island University (LIU), the Natoli Institute features dispensing, formulation, compression, and coating suites.
Supporting one of the few industrial pharmacy programs in North America, the Institute is dedicated to advancing knowledge in the field of pharmaceutical solid oral dosage formulation and engineering.
“The facility features traditional solid dosage formulation equipment, as well as the technology to measure the physical and chemical properties of tablets,” said Dr. Chuck Kettler PhD, director of Natoli Scientific.
Natoli established the Institute to further pharmaceutical compression science and support research into the industry’s most complex challenges. The laboratory will provide research opportunities to undergraduate and graduate students to enable them to find innovative solutions to formulation problems through research and implementation. Work will focus on understanding many of the long time problems associated with the compression of tablets, the development of formulations for new and existing molecules, and the measurements required to ensure proper delivery of formulations to a tablet press and the control of the press.
Together with Natoli Scientific, the Natoli Institute will provide resources to the tableting industry, including new product manufacturing studies, tablet tooling sticking and picking evaluations, and new formulation technologies. Not only does the facility provide an environment for students to learn industrial pharmacy unit operations for solid oral dosage forms, it also provides an opportunity for Natoli customers to have their tableting problems investigated, such as sticking, picking, tablet disintegration/dissolution, bioavailability, and formulation and feasibility experiments.
“We are committed to supporting the future of the industry, as well as providing additional resources to our customers to combat their tableting issues,” said Dale Natoli, company president.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance